Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Simmitinib Versus Investigator's Choice of Chemotherapy for Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma : a Randomised, Open-label, Multicentre, Phase 3 Study

NCT06656091 is registered in ClinicalTrials.gov with Shanghai Runshi Pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT06656091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06656091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Simmitinib Versus Investigator's Choice of Chemotherapy for Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma : a Randomised, Open-label, Multicentre, Phase 3 Study
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2024
Completion date
January 30, 2027
Enrollment
450 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced oesophageal squamous cell carcinoma